Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking
Between the Biotech Waves
00:00
Is Now the Time to IPO?
We think there's roughly 60 to 65 companies queued up. Two-thirds of them are still pretty clinical. There's probably half of those that have INDs targeted for 2024. And they may need to do an additional top-up round to get closer to that. But, you know, our modeling suggests that the IPO market for bio should improve significantly in 2023.
Transcript
Play full episode
